Mark James Litton Athira Pharma, Inc. (ATHA) insider trading activity

ATHA Quotes by TradingView

Mark James Litton is President and CEO of Athira Pharma, Inc.. Currently has a direct ownership of 242,591 shares of ATHA, which is worth approximately $130,999. The most recent transaction as insider was on Jan 02, 2025, when has been sold 25,107 shares (Common Stock) at a price of $0.56 per share, resulting in proceeds of $14,059. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 243K
52.22% 3M change
68.0% 12M change
Total Value Held $130,999

Mark James Litton Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2025
SELL
Open market or private sale
$14,059 $0.56 p/Share
25,107 Reduced 9.38%
242,591 Common Stock
Dec 31 2024
BUY
Exercise of conversion of derivative security
-
108,333 Added 28.81%
267,698 Common Stock
Sep 05 2024
SELL
Open market or private sale
$2,868 $0.57 p/Share
5,032 Reduced 3.06%
159,365 Common Stock
Sep 03 2024
BUY
Grant, award, or other acquisition
-
20,000 Added 10.85%
164,397 Common Stock
Jan 05 2024
SELL
Open market or private sale
$14,026 $2.91 p/Share
4,820 Reduced 3.23%
144,397 Common Stock
Jan 04 2024
BUY
Grant, award, or other acquisition
-
20,000 Added 11.82%
149,217 Common Stock
Nov 18 2022
BUY
Grant, award, or other acquisition
$1,813 $2.74 p/Share
662 Added 0.51%
129,217 Common Stock
Jun 23 2022
SELL
Open market or private sale
$21,412 $2.69 p/Share
7,960 Reduced 5.83%
128,555 Common Stock
Jun 22 2022
BUY
Grant, award, or other acquisition
-
20,000 Added 12.78%
136,515 Common Stock
May 18 2022
BUY
Grant, award, or other acquisition
$5,344 $7.06 p/Share
757 Added 0.65%
116,515 Common Stock
Nov 18 2021
BUY
Grant, award, or other acquisition
$11,071 $12.51 p/Share
885 Added 0.76%
115,758 Common Stock
Aug 17 2021
BUY
Exercise of conversion of derivative security
$68,094 $1.35 p/Share
50,440 Added 30.51%
114,873 Common Stock
May 18 2021
BUY
Grant, award, or other acquisition
$12,528 $14.45 p/Share
867 Added 1.33%
64,433 Common Stock
MJL

Mark James Litton

President and CEO
Bothell, WA

Track Institutional and Insider Activities on ATHA

Follow Athira Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATHA shares.

Notify only if

Insider Trading

Get notified when an Athira Pharma, Inc. insider buys or sells ATHA shares.

Notify only if

News

Receive news related to Athira Pharma, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ATHA